VitaSpring Biomedical Co. Ltd. VSBC
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.21% | -26.69% | -43.72% | -43.34% | -53.17% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | -71.59% | -66.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.08% | -26.44% | -43.40% | -43.98% | -53.40% |
| Operating Income | -10.08% | 26.44% | 43.40% | 43.98% | 53.40% |
| Income Before Tax | -8.77% | 26.32% | 43.32% | 44.74% | 53.95% |
| Income Tax Expenses | -94.25% | -82.52% | -68.42% | -40.56% | -- |
| Earnings from Continuing Operations | 14.15% | 35.70% | 46.41% | 44.37% | 40.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.15% | 35.70% | 46.41% | 44.37% | 40.76% |
| EBIT | -10.08% | 26.44% | 43.40% | 43.98% | 53.40% |
| EBITDA | -10.55% | 26.94% | 44.04% | 44.46% | 53.87% |
| EPS Basic | 8.00% | 35.48% | 45.95% | 43.90% | 41.86% |
| Normalized Basic EPS | 0.00% | 35.29% | 50.00% | 45.83% | 51.85% |
| EPS Diluted | 8.00% | 35.48% | 45.95% | 43.90% | 41.86% |
| Normalized Diluted EPS | 0.00% | 35.29% | 50.00% | 45.83% | 51.85% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |